KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Change in Acquisitions & Divestments (2016 - 2025)

Pfizer (PFE) has disclosed Change in Acquisitions & Divestments for 16 consecutive years, with $4.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 215.29% to $4.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $18.0 billion, a 335.05% increase, with the full-year FY2025 number at $18.0 billion, up 335.05% from a year prior.
  • Change in Acquisitions & Divestments was $4.7 billion for Q4 2025 at Pfizer, up from $2.7 billion in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $35.1 billion in Q4 2022 to a low of $658.0 million in Q1 2024.
  • A 5-year average of $7.8 billion and a median of $5.4 billion in 2021 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: tumbled 92.95% in 2024, then skyrocketed 520.97% in 2025.
  • Pfizer's Change in Acquisitions & Divestments stood at $15.9 billion in 2021, then soared by 121.34% to $35.1 billion in 2022, then crashed by 39.45% to $21.2 billion in 2023, then crashed by 92.95% to $1.5 billion in 2024, then soared by 215.29% to $4.7 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Change in Acquisitions & Divestments are $4.7 billion (Q4 2025), $2.7 billion (Q3 2025), and $6.5 billion (Q2 2025).